Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Unum Group Common Stock (UNM) vs Viatris Inc (VTRS) Price & Performance

Unum Group Common StockTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Unum Group Common Stock vs Viatris Inc — how do they compare? Unum Group Common Stock trades at $91.42 (market cap $14.57B), while Viatris Inc trades at $17.56 (market cap $19.81B). The key difference: Viatris Inc is the larger of the two by market cap, and Viatris Inc pays the higher dividend (2.78%). Which is the better fit depends on your goals — on Pluang, investors hold Unum Group Common Stock for 0 Days and Viatris Inc for 57 Days on average.

UNMVTRS
Market Cap
$14.57B$19.81B
Volume
1,461,5887,547,542
Sector
FinancialsHealth
52-Week High
$96.57$18.27
52-Week Low
$70.66$9.98
Typical Hold Time
0 Days57 Days
Enterprise Value
$18.14B$31.92B
Dividend Yield
2.19%2.78%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Unum Group Common Stock

Unum Group (UNM) trades at $92.05, down 0.5% with neutral technical signals. The stock shows mixed earnings performance with Q1 2026 beating estimates but Q4 2025 and Q2 2026 missing expectations. Analyst consensus is positive with 50% buy ratings and a $101 price target representing 9.7% upside. The company maintains stable profitability with 5.31% net margin and recently announced a $1 billion share repurchase program to enhance shareholder returns.

UNM presents a balanced investment case with strong institutional support and shareholder-friendly capital returns, though earnings consistency remains a concern. The stock trades at reasonable valuations (P/E 21.36, P/S 1.15) with potential upside to analyst targets. Key risks include premium growth sustainability and claims experience volatility in the insurance operations.

Viatris Inc

Viatris (VTRS) trades at $17.44, down 0.57% on the day, with a bullish technical signal supported by moving averages. The company has beaten earnings estimates for three consecutive quarters, though it reported a net loss of $3.51B in 2025. Recent news highlights include FDA approval for WAKIX in Japan and recognition as a top employer. Analyst consensus is mixed with a $22.17 price target representing 27% upside potential.

The stock presents a value opportunity with reasonable P/S and P/B ratios, but faces fundamental challenges including negative profit margins and high debt. Positive cash flow generation and consistent earnings beats provide support, while competitive pressures and execution risks remain concerns for investors seeking turnaround potential in the healthcare sector.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

UNM
100% Buy0% Sell
Avg holding period · 0 Days
VTRS

No sentiment data available yet.

About Unum Group Common Stock

Unum Group provides workplace benefits, including disability, life, accident, critical illness, dental, and vision insurance, along with leave management services. It serves employers through its Unum US, Unum International, and Colonial Life segments, distributing coverage via brokers and independent agents.

Read more on UNM →

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS →